A Phase II/III Trial to Assess the Safety, Immunogenicity and Preliminary Efficacy of Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine Administered to Patients With Non-Small-Cell Lung Cancer (NSCLC) After Receiving Conventional First Line Chemotherapy
The purpose of this study is to determine whether the recombinant human EGF-rP64K/Montanide ISA 51 vaccine is safe, immunogenic and effective in the treatment of stage IIIb/IV non-small-cell lung cancer (NSCLC).
100 项与 Bioven Sdn. Bhd. 相关的临床结果
0 项与 Bioven Sdn. Bhd. 相关的专利（医药）
100 项与 Bioven Sdn. Bhd. 相关的药物交易
100 项与 Bioven Sdn. Bhd. 相关的转化医学
